相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promisingtreatments
T. Jaki et al.
STATISTICS IN MEDICINE (2013)
Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome
Babak Choodari-Oskooei et al.
TRIALS (2013)
A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection
D. Magirr et al.
BIOMETRIKA (2012)
Design Issues in Randomized Phase II/III Trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities
Ruth McNerney et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future
Christian Lienhardt et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Innovative Trial Designs Are Practical Solutions for Improving the Treatment of Tuberculosis
Patrick P. J. Phillips et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
The Prevention and Treatment of Missing Data in Clinical Trials
Roderick J. Little et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Optimal design of multi-arm multi-stage trials
James M. S. Wason et al.
STATISTICS IN MEDICINE (2012)
Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit
Patrick Royston et al.
TRIALS (2011)
Challenges of Phase III study design for trials of new drug regimens for the treatment of TB
Patrick P. J. Phillips et al.
FUTURE MEDICINAL CHEMISTRY (2010)
Global tuberculosis drug development pipeline: the need and the reality
Zhenkun Ma et al.
LANCET (2010)
Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis
David J. Horne et al.
LANCET INFECTIOUS DISEASES (2010)
Some drop-the-loser designs for monitoring multiple doses
Y. H. Joshua Chen et al.
STATISTICS IN MEDICINE (2010)
Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activity
Geraint R. Davies
TUBERCULOSIS (2010)
Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
Susan E. Dorman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Stopping clinical trials early for benefit: impact on estimation
Boris Freidlin et al.
CLINICAL TRIALS (2009)
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
Marcus B. Conde et al.
LANCET (2009)
How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design - a reanalysis of 4 trials
F. M-S Barthel et al.
TRIALS (2009)
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
Matthew R. Sydes et al.
TRIALS (2009)
Multi-arm clinical trials of new agents: Some design considerations
Boris Freidlin et al.
CLINICAL CANCER RESEARCH (2008)
Speeding up the evaluation of new agents in cancer
Mahesh K. B. Parmar et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Design issues in pivotal drug trials for drug sensitive tuberculosis (TB)
Andrew J. Nunn et al.
TUBERCULOSIS (2008)
Stopping at nothing? Some dilemmas of data monitoring in clinical trials
Steven N. Goodman
ANNALS OF INTERNAL MEDICINE (2007)
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis
William J. Burman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
分享论文
